Released May 6, 2021, after the close
10-Q filed May 6, 2021, 36 days after period end · 0001564590-21-024932
Q1 2021 · 10-Q
Revenue$7.30M$7.30M +4,219.5% vs Q1 2020no prior Q4 2020 on file
Net Income-$19.40M-$19.40M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.66-$0.66 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$19,403,000N/M
Operating Cash Flow-$15,479,000N/M
Margins · derived
Operating margin-265.8%+13237.8 pt vs Q1 2020
Net margin-265.8%+13521.2 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $7.30M | $169.00K | $3.81M | $1.15M |
| Net Income | -$19.40M | -$23.30M | -$5.10M | -$10.64M |
| EPS Diluted | -$0.66 | -$1.22 | -$0.29 | -$0.74 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR